None of the other de novo SNVs (i.e., BCL11A, BCOR, and COL1A1) was recurrent in more than one sample nor has been linked to treatment failure in breast cancer, leaving the evolution of resistance unexplained in 12 of 13 replicates (Supplementary Table S1). This evidence concerns the gene BCL11A and breast cancer.